Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1231-1236, September 2010

Corticosteroid Dose as a Risk Factor for Avascular Necrosis of the Bone after Hematopoietic Cell Transplantation

  • Sarah McAvoy

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
  • ,
  • K. Scott Baker

      Affiliations

    • Survivorship Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • ,
  • Daniel Mulrooney

      Affiliations

    • Division of Pediatric Hematology-Oncology, University of Minnesota, Minneapolis, Minnesota
  • ,
  • Anne Blaes

      Affiliations

    • Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
  • ,
  • Mukta Arora

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
  • ,
  • Linda J. Burns

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
  • ,
  • Navneet S. Majhail

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests to: Navneet Majhail, MD, MS, Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455.

Received 4 January 2010; accepted 7 March 2010. published online 18 March 2010.

Exposure to corticosteroids increases the risks of avascular necrosis (AVN) of the bone after hematopoietic cell transplantation (HCT). However, whether this effect is dependent on the dose of corticosteroids is not well known. We conducted a case-controlled study, which included 74 recipients of autologous or allogeneic HCT with AVN and 147 controls without AVN that were matched by age, sex, and year of HCT to cases. Cases with AVN included 8 autologous HCT recipients, 58 myeloablative allogeneic HCT recipients, and 8 recipients of nonmyeloabalative allogeneic HCT. Corticosteroid exposure was expressed as cumulative doses of prednisone. Cases received higher cumulative doses of prednisone than controls, and among allogeneic HCT recipients, cases were more likely to have developed acute and chronic graft-versus-host disease (aGVHD, cGVHD). Cumulative dose of prednisone was an independent risk factor for AVN. Compared to no corticosteroid exposure, exposure to <3870 mg cumulative dose of prednisone was associated with 4.0 (95% confidence intervals, 1.5-11.2) times higher risk, 3870-9735 mg with 5.6 (2.1-15.2) times higher risk and >9735 with 8.6 (3.2-23.5) times higher risk of AVN. Exposure to higher doses of corticosteroids increases the risk of AVN in HCT recipients.

Key Words: Allogeneic hematopoietic cell transplantation, Autologous hematopoietic-cell transplantation, Avascular necrosis of bone, Late complications

 

 Financial disclosure: See Acknowledgments on page 1236.

PII: S1083-8791(10)00113-8

doi:10.1016/j.bbmt.2010.03.008

Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1231-1236, September 2010